{"id":"10rac-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (metronidazole-related)"},{"rate":null,"effect":"Metallic taste (metronidazole-related)"},{"rate":null,"effect":"Immune-related adverse events (10RAC-related)"}]},"_chembl":{"chemblId":"CHEMBL137","moleculeType":"Small molecule","molecularWeight":"171.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"10RAC appears to be an immunotherapeutic agent designed to activate anti-tumor immunity, while metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain parasites. The combination may leverage metronidazole's immunomodulatory properties alongside 10RAC's direct anti-cancer mechanism, though the precise synergy is not well-characterized in public literature.","oneSentence":"10RAC is a recombinant anti-cancer immunotherapy combined with metronidazole, an antimicrobial agent, to enhance anti-tumor immune response while treating anaerobic infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:24:34.560Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication unclear from available data)"}]},"trialDetails":[{"nctId":"NCT01572597","phase":"PHASE4","title":"Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2011-06","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pariet","Klaricid","Hiconcil","Flagyl"],"phase":"marketed","status":"active","brandName":"10RAC+metronidazole","genericName":"10RAC+metronidazole","companyName":"Buddhist Tzu Chi General Hospital","companyId":"buddhist-tzu-chi-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"10RAC is a recombinant anti-cancer immunotherapy combined with metronidazole, an antimicrobial agent, to enhance anti-tumor immune response while controlling microbial burden. Used for Cancer (specific indication not clearly defined in available literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}